EP3227339
BLENDINGSMÓTEFNAVIÐTAKAR SEM MIÐA Á G-PRÓTEINTENGDAN VIÐTAKA OG NOTKUN ÞEIRRA
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
4.12.2015EP published:
10.11.2021EP application number:
15865633.0
EP translation filed:
13.1.2022Grant published:
15.2.2022EPO information:
European Patent Register
Max expiry date:
3.12.2035Expiry date:
3.12.2024
Title in English:
CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR AND USES THEREOFLanguage of the patent:
English
Timeline
Today
4.12.2015EP application
10.11.2021EP Publication
13.1.2022Translation submitted
15.2.2022Registration published
3.12.2024Expires
Owner
Name:
Memorial Sloan-Kettering Cancer CenterAddress:
1275 York Avenue, New York, NY 10065, US
Name:
Eureka Therapeutics, Inc.Address:
5858 Horton Street, Suite 362, Emeryville, CA 94608, US
Inventor
Name:
BRENTJENS, Renier J.Address:
New York, NY 10021, US
Name:
SMITH, Eric L.Address:
New York, NY 10021, US
Name:
LIU, ChengAddress:
Emeryville, CA 94608, US
Name:
LIU, HongAddress:
El Sorbrante, CA 94803, US
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
201462088286 PDate:
5.12.2014Country:
US
Classification
Categories:
A61P 35/00, A61P 43/00, C07K 16/28, C07K 14/725
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 14.12.2021
Expires: 3.12.2022
Payer: Patice ehf.
Number: 8
Paid: 9.11.2022
Expires: 3.12.2023
Payer: Árnason Faktor ehf.
Number: 9
Paid: 15.11.2023
Expires: 3.12.2024
Payer: Árnason Faktor ehf.